Payment overview · 2025
General Payments
$1,043.42
44 reported records · 14 companies
Healthcare provider profile · identity verified
James Jung, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1912920919
Verified facts
What the public records show
CMS Open Payments records show James Jung, MD received $1,043.42 in general payments during 2025 across 44 reported records.
Ardelyx, Inc. accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Farxiga, Kerendia, Linzess, Ozempic, Shingrix, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 652 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viberzi by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 445 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $228.15 | 21.9% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $202.90 | 19.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $131.16 | 12.6% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $126.90 | 12.2% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.53 | 6.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.59 | 5.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.77 | 5.0% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 4.1% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $29.86 | 2.9% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $23.16 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.78 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.39 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.33 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.40 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,000.92 | 43 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $228.15 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $202.90 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $131.16 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.59 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.59 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $51.77 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.36 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 652 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 149 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 165 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 191 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 297 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 45 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
652 | 176 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
191 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
165 | 24 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
45 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
445 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
297 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1545 | 374 |
| Celecoxib | Celecoxib | 1373 | 383 |
| Amlodipine Besylate | Amlodipine Besylate | 1102 | 274 |
| Metformin Hcl | Metformin Hcl | 933 | 239 |
| Losartan Potassium | Losartan Potassium | 858 | 207 |
| Omeprazole | Omeprazole | 797 | 208 |
| Vascepa | Icosapent Ethyl | 712 | 125 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 705 | 189 |
| Tamsulosin Hcl | Tamsulosin Hcl | 681 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 662 | 141 |
| Creon | Lipase/Protease/Amylase | 652 | 176 |
| Famotidine | Famotidine | 651 | 177 |
| Donepezil Hcl | Donepezil Hcl | 600 | 128 |
| Clopidogrel | Clopidogrel Bisulfate | 588 | 115 |
| Montelukast Sodium | Montelukast Sodium | 569 | 143 |
| Levofloxacin | Levofloxacin | 531 | 281 |
| Lidocaine | Lidocaine | 509 | 108 |
| Simvastatin | Simvastatin | 476 | 115 |
| Fenofibrate | Fenofibrate | 471 | 123 |
| Finasteride | Finasteride | 462 | 107 |
| Jardiance | Empagliflozin | 445 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 429 | 88 |
| Zolpidem Tartrate | Zolpidem Tartrate | 424 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 103 |
| Tradjenta | Linagliptin | 383 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 353 | 139 |
| Restasis | Cyclosporine | 352 | 81 |
| Ursodiol | Ursodiol | 352 | 67 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 325 | 52 |
| Azithromycin | Azithromycin | 309 | 194 |
| Gabapentin | Gabapentin | 302 | 72 |
| Ibuprofen | Ibuprofen | 299 | 129 |
| Fluocinonide | Fluocinonide | 298 | 92 |
| Baclofen | Baclofen | 297 | 98 |
| Ozempic | Semaglutide | 297 | 46 |
| Pregabalin | Pregabalin | 296 | 60 |
| Allopurinol | Allopurinol | 290 | 66 |
| Bethanechol Chloride | Bethanechol Chloride | 261 | 63 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 261 | 45 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 240 | 67 |
| Alprazolam | Alprazolam | 236 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 235 | 57 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 234 | 172 |
| Ibandronate Sodium | Ibandronate Sodium | 227 | 67 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 223 | 45 |
| Furosemide | Furosemide | 220 | 62 |
| Potassium Chloride | Potassium Chloride | 220 | 59 |
| Clonazepam | Clonazepam | 216 | 64 |
| Amoxicillin | Amoxicillin | 214 | 118 |
| Memantine Hcl Er | Memantine Hcl | 196 | 39 |
| Glimepiride | Glimepiride | 194 | 41 |
| Linzess | Linaclotide | 191 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 46 |
| Lorazepam | Lorazepam | 186 | 42 |
| Januvia | Sitagliptin Phosphate | 185 | 32 |
| Metoclopramide Hcl | Metoclopramide Hcl | 181 | 57 |
| Dicyclomine Hcl | Dicyclomine Hcl | 177 | 77 |
| Xarelto | Rivaroxaban | 177 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 169 | 49 |
| Dexlansoprazole Dr | Dexlansoprazole | 168 | 36 |
| Kerendia | Finerenone | 165 | 24 |
| Icosapent Ethyl | Icosapent Ethyl | 158 | 90 |
| Mupirocin | Mupirocin | 155 | 63 |
| Farxiga | Dapagliflozin Propanediol | 149 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 148 | 110 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 148 | 37 |
| Estradiol | Estradiol | 147 | 42 |
| Prednisone | Prednisone | 146 | 110 |
| Trazodone Hcl | Trazodone Hcl | 146 | 38 |
| Meloxicam | Meloxicam | 145 | 33 |
| Megestrol Acetate | Megestrol Acetate | 141 | 55 |
| Tramadol Hcl | Tramadol Hcl | 140 | 51 |
| Cyclosporine | Cyclosporine | 139 | 86 |
| Ketoconazole | Ketoconazole | 139 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | 33 |
| Raloxifene Hcl | Raloxifene Hcl | 134 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 42 |
| Eliquis | Apixaban | 132 | 23 |
| Glipizide | Glipizide | 132 | 35 |
| Entresto | Sacubitril/Valsartan | 128 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 124 | 29 |
| Clonidine Hcl | Clonidine Hcl | 123 | 21 |
| Carvedilol | Carvedilol | 115 | 23 |
| Methimazole | Methimazole | 115 | 21 |
| Temazepam | Temazepam | 112 | 35 |
| Bupropion Hcl Sr | Bupropion Hcl | 111 | 29 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 108 | 31 |
| Myrbetriq | Mirabegron | 105 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 104 | 33 |
| Dutasteride | Dutasteride | 102 | 28 |
| Amantadine | Amantadine Hcl | 98 | 81 |
| Nateglinide | Nateglinide | 96 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 29 |
| Pilocarpine Hcl | Pilocarpine Hcl | 92 | 24 |
| Cephalexin | Cephalexin | 90 | 49 |
| Minoxidil | Minoxidil | 90 | 21 |
| Sertraline Hcl | Sertraline Hcl | 90 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | 17 |
| Tadalafil | Tadalafil | 89 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 88 | 14 |
| Hydrocortisone | Hydrocortisone | 85 | 34 |
| Alendronate Sodium | Alendronate Sodium | 84 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 15 |
| Methotrexate | Methotrexate Sodium | 82 | 13 |
| Valacyclovir | Valacyclovir Hcl | 81 | 40 |
| Metolazone | Metolazone | 79 | 20 |
| Acyclovir | Acyclovir | 77 | 48 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 77 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 15 |
| Latanoprost | Latanoprost | 75 | 16 |
| Bupropion Hcl | Bupropion Hcl | 72 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 70 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 68 | 16 |
| Clotrimazole | Clotrimazole | 68 | 26 |
| Desmopressin Acetate | Desmopressin Acetate | 66 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 30 |
| Ciclopirox | Ciclopirox Olamine | 64 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 60 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 60 | 18 |
| Atenolol | Atenolol | 59 | 12 |
| Econazole Nitrate | Econazole Nitrate | 59 | 30 |
| Entecavir | Entecavir | 59 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 59 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 13 |
| Fenofibrate | Fenofibrate,micronized | 55 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 12 |
| Carbamazepine | Carbamazepine | 53 | 20 |
| Lactated Ringers | Ringer's Solution,lactated | 53 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 22 |
| Azelastine Hcl | Azelastine Hcl | 50 | 17 |
| Nitroglycerin | Nitroglycerin | 50 | 20 |
| Primidone | Primidone | 50 | 13 |
| Loperamide | Loperamide Hcl | 46 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 35 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 45 | 35 |
| Cholestyramine | Cholestyramine (With Sugar) | 44 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 44 | 20 |
| Cilostazol | Cilostazol | 42 | suppressed |
| Lisinopril | Lisinopril | 42 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 39 | 16 |
| Spironolactone | Spironolactone | 39 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 14 |
| Naproxen | Naproxen | 36 | 15 |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Famciclovir | Famciclovir | 35 | 28 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Dexilant | Dexlansoprazole | 32 | suppressed |
| Procto-Med Hc | Hydrocortisone | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 30 | 11 |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 28 | 17 |
| Unifine Pentips | Pen Needle, Diabetic | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 15 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 12 |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Prolia | Denosumab | 27 | 21 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Ciclopirox | Ciclopirox | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 24 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Albendazole | Albendazole | 21 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 21 | 19 |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 12 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Sodium Fluoride | Fluoride (Sodium) | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Ztlido | Lidocaine | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dupixent Syringe | Dupilumab | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Vyzulta | Latanoprostene Bunod | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 14 | 11 |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,043.42 · 44 records | Ardelyx, Inc. | AFREZZA, AIRSUPRA, AREXVY, BARRIGEL, CREON, FARXIGA, Gocovri, IBSRELA, Kerendia, LINZESS, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, Tresiba, VERQUVO, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error